🚀 VC round data is live in beta, check it out!
Mankind Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mankind Pharma and similar public comparables like Praxis Precision Medicines, Fosun Pharma, Salubris Pharmaceuticals, Haisco Pharmaceutical and more.
Mankind Pharma Overview
About Mankind Pharma
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
Founded
1991
HQ
Employees
18.6K
Website
Financials (LTM)
EV
$10B
Mankind Pharma Financials
Mankind Pharma reported last 12-month revenue of $2B and EBITDA of $380M.
In the same LTM period, Mankind Pharma generated $1B in gross profit, $380M in EBITDA, and $207M in net income.
Revenue (LTM)
Mankind Pharma P&L
In the most recent fiscal year, Mankind Pharma reported revenue of $1B and EBITDA of $382M.
Mankind Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $928M | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $380M | XXX | $382M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $207M | XXX | $232M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | — | — | $868M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mankind Pharma Stock Performance
Mankind Pharma has current market cap of $9B, and enterprise value of $10B.
Market Cap Evolution
Mankind Pharma's stock price is $22.82.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $9B | 1.2% | XXX | XXX | XXX | $0.56 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMankind Pharma Valuation Multiples
Mankind Pharma trades at 6.4x EV/Revenue multiple, and 26.1x EV/EBITDA.
EV / Revenue (LTM)
Mankind Pharma Financial Valuation Multiples
As of April 18, 2026, Mankind Pharma has market cap of $9B and EV of $10B.
Equity research analysts estimate Mankind Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mankind Pharma has a P/E ratio of 45.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV/Revenue | 6.4x | XXX | 7.0x | XXX | XXX | XXX |
| EV/EBITDA | 26.1x | XXX | 26.0x | XXX | XXX | XXX |
| EV/EBIT | 34.5x | XXX | 34.9x | XXX | XXX | XXX |
| EV/Gross Profit | 9.1x | XXX | 10.7x | XXX | XXX | XXX |
| P/E | 45.4x | XXX | 40.7x | XXX | XXX | XXX |
| EV/FCF | 42.5x | XXX | 49.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mankind Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mankind Pharma Margins & Growth Rates
Mankind Pharma's revenue in the last 12 month grew by 12%.
Mankind Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Mankind Pharma's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mankind Pharma's rule of X is 58% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Mankind Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | (1%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 58% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mankind Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Health & Beauty comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mankind Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Praxis Precision Medicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Fosun Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Salubris Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Haisco Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Baxter International | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mankind Pharma M&A Activity
Mankind Pharma acquired XXX companies to date.
Last acquisition by Mankind Pharma was on XXXXXXXX, XXXXX. Mankind Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mankind Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMankind Pharma Investment Activity
Mankind Pharma invested in XXX companies to date.
Mankind Pharma made its latest investment on XXXXXXXX, XXXXX. Mankind Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mankind Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mankind Pharma
| When was Mankind Pharma founded? | Mankind Pharma was founded in 1991. |
| Where is Mankind Pharma headquartered? | Mankind Pharma is headquartered in India. |
| How many employees does Mankind Pharma have? | As of today, Mankind Pharma has over 18K employees. |
| Who is the CEO of Mankind Pharma? | Mankind Pharma's CEO is Sheetal Arora. |
| Is Mankind Pharma publicly listed? | Yes, Mankind Pharma is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Mankind Pharma? | Mankind Pharma trades under MANKIND ticker. |
| When did Mankind Pharma go public? | Mankind Pharma went public in 2023. |
| Who are competitors of Mankind Pharma? | Mankind Pharma main competitors are Praxis Precision Medicines, Fosun Pharma, Salubris Pharmaceuticals, Haisco Pharmaceutical. |
| What is the current market cap of Mankind Pharma? | Mankind Pharma's current market cap is $9B. |
| What is the current revenue of Mankind Pharma? | Mankind Pharma's last 12 months revenue is $2B. |
| What is the current revenue growth of Mankind Pharma? | Mankind Pharma revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Mankind Pharma? | Current revenue multiple of Mankind Pharma is 6.4x. |
| Is Mankind Pharma profitable? | Yes, Mankind Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mankind Pharma? | Mankind Pharma's last 12 months EBITDA is $380M. |
| What is Mankind Pharma's EBITDA margin? | Mankind Pharma's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Mankind Pharma? | Current EBITDA multiple of Mankind Pharma is 26.1x. |
| What is the current FCF of Mankind Pharma? | Mankind Pharma's last 12 months FCF is $234M. |
| What is Mankind Pharma's FCF margin? | Mankind Pharma's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of Mankind Pharma? | Current FCF multiple of Mankind Pharma is 42.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.